John Wiley & Sons Inc Dossier
Qualitative Analysis
Business overview
John Wiley & Sons, Inc. (NYSE: WLY, WLYB) is a global leader in research publishing and digital learning. Founded in 1807 and headquartered in Hoboken, New Jersey, the company operates primarily through two core segments: Research and Learning. The Research segment provides scientific, technical, medical, and scholarly journals, subscription models, and open-access publishing. The Learning segment delivers digital courseware, professional assessments, and educational books. Wiley has increasingly positioned itself as a critical content and data provider for the AI-driven knowledge economy, licensing its vast library of trusted scientific literature to train artificial intelligence models.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the monetization of Wiley's authoritative content and research intelligence through AI training models, content licensing, and clinical workflow integrations.
Expected impact: Aims to exceed $50 million in AI revenue in FY27 and scale recurring AI revenue by 2x to 3x.
Streamlining the organization, rightsizing the cost structure, and optimizing technology costs to drive greater profitability and cash flow.
Expected impact: Targeting annualized cost savings of approximately $100 million.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Strategic Partnerships
Virtusa assumed ownership of Wiley's Sri Lanka technology operations to optimize Wiley's technology foundation, modernize enterprise technology, and reduce costs.
Terms: Assumed ownership of Sri Lanka technology operations; financial terms not fully disclosed.
Brings Wiley's trusted scientific and medical content (including Cochrane Database of Systematic Reviews) into the OpenEvidence medical AI platform used by U.S. physicians.
Terms: Licensing agreement; terms not disclosed.
Co-hosted executive summits and released cross-sector intelligence reports to connect evidence creation with real-world clinical applications.
Terms: Collaborative partnership; terms not disclosed.